ALK(SZ:002940) Mei Ri Jing Ji Xin Wen·2025-10-19 07:53Core Viewpoint - The company, Anglikon (002940), has announced that it currently has only one innovative drug project, ALK-N001, which is in Phase I clinical trials as of the date of the announcement [1] Group 1: Drug Development Status - The only drug project in development is ALK-N001, which is still in Phase I clinical trials [1] - A strategic cooperation agreement regarding the ALK-N002 project was signed with Afei (Shanghai) Biopharmaceutical Technology Co., Ltd. and Shanghai Qinhuali Biopharmaceutical Technology Co., Ltd. on August 26, 2025 [1] - The agreement has been approved by the company's shareholders, and the partners are currently undergoing internal approval processes [1] Group 2: Investor Advisory - The company has issued a reminder to investors to make rational decisions and be aware of investment risks [1]